AI Biocomputing Big Model Global Market Report 2026

The artificial intelligence (AI) biocomputing big model market size has grown exponentially in recent years. It will grow from $4.38 billion in 2025 to $5.29 billion in 2026 at a compound annual growth rate (CAGR) of 20.6%. The growth in the historic period can be attributed to growth in genomics and proteomics research, increasing computational biology initiatives, adoption of deep learning frameworks, expansion of pharmaceutical and biotech R&D, rising need for molecular interaction prediction.

The artificial intelligence (AI) biocomputing big model market size is expected to see exponential growth in the next few years. It will grow to $11.27 billion in 2030 at a compound annual growth rate (CAGR) of 20.8%. The growth in the forecast period can be attributed to increasing deployment of hybrid AI biocomputing systems, growing demand for personalized medicine applications, rising adoption of large biological models, expansion of cloud-based bioinformatics services, increasing integration with healthcare and agricultural data. Major trends in the forecast period include increasing adoption of cloud-based bioinformatics platforms, rising demand for high-performance computing hardware, growing integration of multi-omics data analysis tools, expansion of simulation and digital twin software applications, rising focus on training and education services for ai biocomputing.

The increasing demand for personalized medicine is anticipated to fuel the expansion of the artificial intelligence (AI) biocomputing big model market in the coming years. Personalized medicine refers to customizing healthcare interventions according to an individual’s genetic, molecular, and clinical attributes. Progress in genomic and other high-throughput biological technologies has substantially expanded the volume and complexity of patient data, generating a requirement for advanced computational methods to derive clinically meaningful insights. AI biocomputing big models are large-scale AI systems capable of processing multi-modal datasets such as genomics, proteomics, medical imaging, and electronic health records, supporting personalized medicine by facilitating disease risk prediction, treatment optimization, and therapy customization at scale. For example, in February 2024, as reported by the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Therefore, the rising demand for personalized medicine is propelling the growth of the artificial intelligence (AI) biocomputing big model market.

The expansion of pharmaceutical research and development (R&D) initiatives is projected to stimulate the growth of the AI biocomputing big model market. Pharmaceutical R&D encompasses structured efforts by drug manufacturers, biotechnology firms, and research organizations to discover, develop, and refine new therapies. Growing investment in pharmaceutical R&D is driven by the necessity to enhance drug discovery efficiency, shorten development timelines, and tackle complex diseases, thereby heightening reliance on advanced computational technologies. AI biocomputing big models serve a vital function in pharmaceutical R&D by facilitating large-scale analysis of multi-omics data, molecular structures, clinical trial information, and real-world evidence. These models assist in target identification, lead optimization, toxicity forecasting, and patient stratification, thereby strengthening decision-making throughout the drug development pipeline. For example, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government’s net spending on research and development rose to £17.4 billion ($22.1 billion), compared with £16.1 billion ($20.45 billion) in 2022, marking an 8.2% increase. Therefore, the growth in research and development activities is driving the expansion of the AI biocomputing big model market.

The expanding use of health monitoring devices is expected to accelerate the growth of the AI biocomputing big model market in the foreseeable future. Health monitoring devices are medical or wearable technologies intended to continuously or periodically gather and evaluate physiological data to determine an individual’s health condition and support timely medical care. The rising adoption of health monitoring devices is fueled by the increasing prevalence of chronic diseases, as continuous real-time tracking allows early intervention, improved disease management, and lower hospitalization rates. AI biocomputing big models strengthen health monitoring devices by processing large-scale, multi-parameter physiological data in real time to identify subtle patterns, forecast health risks, deliver personalized insights, and enable proactive, precision-focused interventions. For example, in August 2025, as reported by the Office of Inspector General, a US-based independent organization, the number of Medicare beneficiaries utilizing remote patient monitoring grew substantially, reaching nearly 1 million in 2024, representing a 27% increase compared to 2023. Therefore, the increasing adoption of health monitoring devices is propelling the growth of the AI biocomputing big model market.

Major companies operating in the artificial intelligence (AI) biocomputing big model market are Microsoft Corporation, Alibaba Group Holding Limited, Huawei Technologies Co. Ltd., Siemens AG, International Business Machines Corporation, Oracle Corporation, Nvidia Corporation, Generate Biomedicines Inc., Owkin Inc., Nabla Bio Inc., Arzeda Corp., Evozyne Inc., BigHat Biosciences Inc., AI Proteins Inc., Cradle B.V., Profluent Bio Inc., Absci Corporation, Biomatter Designs UAB, Insilico Medicine Ltd., and Variant Bio Inc.

North America was the largest region in the artificial intelligence (AI) biocomputing big model market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) biocomputing big model market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) biocomputing big model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI) biocomputing big model market includes revenues earned by entities providing services such as model training and fine-tuning, cloud-based model hosting and inference, custom model development, and integration into enterprise or research workflows. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The artificial intelligence (AI) biocomputing big model market consists of sales of products such as large-scale biological foundation models, genomic and proteomic prediction engines, molecular simulation AI systems, drug discovery models, and multimodal bio-AI models. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

An artificial intelligence (AI) biocomputing big model is a large-scale AI system designed to analyze complex biological and biomedical data, including genomics, proteomics, and multi-omics datasets. It uses deep learning and generative modeling to predict molecular interactions, identify biomarkers, and support applications such as personalized medicine and drug discovery.

The primary components of artificial intelligence biocomputing big model include hardware, software, and services. Hardware includes high-performance computing systems and processors used to support complex biological data analysis and large-scale model training. These solutions incorporate models such as large biological models, deep learning frameworks, bioinformatics platforms, and simulation and digital twin software. Deployment occurs through on-premises, cloud-based, and hybrid models. Applications include genome sequencing, protein structure prediction, and other areas, serving end users such as pharmaceutical and biotechnology companies, research institutions and academia, healthcare providers, agricultural firms, environmental and conservation organizations, and government research labs.

Tariffs on imported high-performance computing hardware, AI accelerators, and specialized bioinformatics equipment are impacting the AI biocomputing big model market by increasing production and deployment costs, particularly affecting hardware and cloud deployment segments. Regions such as North America, Europe, and Asia-Pacific, which rely on imported servers, GPUs, and data storage systems, are most affected. While tariffs raise costs, they also encourage local manufacturing, drive regional innovation in cost-efficient AI hardware, and promote domestic service providers, supporting long-term market resilience and self-reliance.

The artificial intelligence (AI) biocomputing big model market research report is one of a series of new reports that provides artificial intelligence (AI) biocomputing big model market statistics, including artificial intelligence (AI) biocomputing big model industry global market size, regional shares, competitors with a artificial intelligence (AI) biocomputing big model market share, detailed artificial intelligence (AI) biocomputing big model market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) biocomputing big model industry. This artificial intelligence (AI) biocomputing big model market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.